Finasteride Tablet, Film Coated
Product Images NDC 68071-3785

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 68071-3785). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3785 8)

Finasteride 5 mg film-coated tablets label from NuCare Pharmaceuticals, Inc. The label indicates a quantity of 180 tablets, each containing 5 mg of Finasteride. It includes warnings about use by women and children, storage instructions at 68-77°F, and details about the tablet appearance: circular, biconvex, beveled edged, blue colored with 'E' on one side and '61' on the other. Manufacturer and packaging information from Aurobindo Pharma Limited, India, is also shown.*

FDA Label Image

Figure 1 Symptom Score In A Long-term Efficacy And Safety Study (Finasteride Fig1)

A line graph titled 'Symptom Score in a Long-Term Efficacy and Safety Study' showing mean change from baseline with standard error over four years. Two lines represent placebo and Finasteride groups, with Finasteride showing a greater decrease in symptom score over time compared to placebo. Sample sizes for each group at baseline and years 1 to 4 are also indicated.*

FDA Label Image

Figure 2 Percent Of Patients Having Surgery For Bph, Including Turp (Finasteride Fig2)

A line graph titled 'Percent of Patients Having Surgery for BPH, Including TURP' comparing finasteride and placebo groups over 48 months. The y-axis shows percent of patients up to 15%, and the x-axis is observation time in months. The graph shows lower surgery rates in the finasteride group versus placebo. Below the graph is a table listing cumulative events and patients at risk per year for each group.*

FDA Label Image

Figure3 (Finasteride Fig3)

A line graph titled "Percent of Patients Developing Acute Urinary Retention (Spontaneous and Precipitated)" comparing Finasteride and Placebo groups over 48 months. The x-axis shows observation time in months, and the y-axis shows percent of patients from 0% to 15%. The graph includes cumulative event counts and patients at risk per year for both groups below the plot.*

FDA Label Image

Figure4 (Finasteride Fig4)

A line graph titled 'Prostate Volume in a Long-Term Efficacy and Safety Study' showing mean percent change from baseline in prostate volume over four years. The graph compares placebo and finasteride groups, indicating an increase in prostate volume for placebo and a decrease for finasteride across the study period, with sample sizes for each group listed by year.*

FDA Label Image

Figure5 (Finasteride Fig5)

A line graph titled 'Cumulative Incidence of a 4-Point Rise in AUA Symptom Score by Treatment Group' showing percent with event on the y-axis and years from randomization on the x-axis. Four treatment groups are compared: Placebo, Finasteride, Doxazosin, and Combination, with Placebo showing the highest cumulative incidence and Combination the lowest over 5.5 years.*

FDA Label Image

Chemical Structure (Finasteride Str)

Chemical structure of finasteride, a steroidal compound with multiple rings including a lactam group and various methyl substituents, depicted in a line drawing with bond configurations.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.